The FDA approved Lumvoa (veligrotug-vvze), Viridian Therapeutics' antibody treatment for thyroid eye disease, on June 26, 2026, and the company said the drug launched immediately. It is the second therapy targeting the IGF-1R pathway cleared for the condition, and the first approved for use across both active and chronic stages of the disease.
Newspaper Daily publishes information, not medical advice. The outlet reports on regulatory actions and research findings and does not provide diagnosis or treatment guidance.
What thyroid eye disease is
Thyroid eye disease is an autoimmune condition, most often associated with Graves' disease, in which inflammation and swelling of the tissues and muscles around the eyes cause bulging, double vision, pressure, and in severe cases vision-threatening compression. Until recently, options beyond surgery and steroids were limited.
The first IGF-1R antibody, Tepezza (teprotumumab), was approved in 2020 but is used mainly in the active phase of disease. Per coverage in Nature Reviews Drug Discovery, veligrotug's approval extends targeted therapy to patients whose disease has burned out into its chronic stage.
Related stories: FDA Approves First-Ever Treatment for Menkes Disease in Children · FDA Approves Zidesamtinib for ROS1-Positive Lung Cancer After Progression.
What this approval can and cannot show
Trial programs for the drug reported improvements in eye protrusion and double vision over a 12-week infusion course, but trial populations were selected, and the approval does not show how durable the benefit is over years or how the drug compares head-to-head with Tepezza. Hearing changes and infusion reactions, effects seen in the IGF-1R class, require monitoring, and labeling details govern who should not receive the therapy.
When to talk to a clinician
People with thyroid eye disease should discuss staging, smoking cessation, and thyroid control with their endocrinologist and ophthalmologist before considering targeted therapy, since disease activity drives both eligibility and timing.
Cost is another open question: specialty biologics for a rare indication often carry list prices that limit access, and payer coverage policies were still being set in the weeks after launch.